Unicycive Therapeutics, Inc. UNCY
We take great care to ensure that the data presented and summarized in this overview for Unicycive Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding UNCY
View all-
Vivo Capital, LLC Palo Alto, CA11.4MShares$56.5 Million1.76% of portfolio
-
Great Point Partners LLC Greenwich, CT11MShares$54.6 Million3.87% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$49.7 Million1.9% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT9.39MShares$46.7 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$25.2 Million0.56% of portfolio
-
Walleye Capital LLC Plymouth, MN4.09MShares$20.3 Million0.01% of portfolio
-
Silverarc Capital Management, LLC2.41MShares$12 Million0.33% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA2.35MShares$11.7 Million2.54% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.75MShares$8.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$6.03 Million0.0% of portfolio
Latest Institutional Activity in UNCY
Top Purchases
Top Sells
About UNCY
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Insider Transactions at UNCY
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Gaurav Aggarwal Director |
BUY
Conversion of derivative security
|
Indirect |
1,400,000
+10.96%
|
-
|
|
Oct 09
2024
|
Gaurav Aggarwal Director |
BUY
Conversion of derivative security
|
Indirect |
5,500,000
+35.55%
|
-
|
|
Jul 11
2023
|
Gaurav Aggarwal Director |
BUY
Conversion of derivative security
|
Indirect |
3,470,152
+50.0%
|
-
|
|
Jul 11
2023
|
Douglas Jermasek EVP of Corporate Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
104,612
+37.41%
|
-
|
|
Jul 11
2023
|
Pramod Gupta EVP, Pharmaceuticals and BD |
BUY
Exercise of conversion of derivative security
|
Direct |
41,845
+50.0%
|
-
|
|
Jul 11
2023
|
Shalabh K. Gupta CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
104,612
+3.97%
|
-
|
|
Jul 15
2022
|
Brigitte Schiller Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,738
+50.0%
|
-
|
|
May 16
2022
|
Brigitte Schiller Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$0
$0.82 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 6.9M shares |
|---|